Pfizer Receives FDA Approval for Cibinqo in Adolescents with Atopic Dermatitis

Pfizer today announced that the FDA has approved Cibinqo (abrocitinib) for the treatment of refractory moderate-to-severe atopic dermatitis in adolescents aged 12 to 17 years whose disease is not adequately controlled with other systemic therapies.